Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned an average rating of “Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $59.60.

JANX has been the subject of a number of research reports. Cantor Fitzgerald started coverage on Janux Therapeutics in a report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 target price for the company. BTIG Research initiated coverage on Janux Therapeutics in a research report on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price on the stock. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, February 27th. Bank of America raised their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th. Finally, Wedbush reissued an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 11th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in JANX. Vanguard Group Inc. boosted its holdings in shares of Janux Therapeutics by 3.9% in the 4th quarter. Vanguard Group Inc. now owns 979,483 shares of the company’s stock valued at $10,510,000 after buying an additional 37,202 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Janux Therapeutics by 174.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 39,948 shares of the company’s stock valued at $429,000 after acquiring an additional 25,404 shares during the last quarter. Barclays PLC grew its position in shares of Janux Therapeutics by 166.3% in the 4th quarter. Barclays PLC now owns 47,722 shares of the company’s stock valued at $511,000 after acquiring an additional 29,800 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Janux Therapeutics by 22.3% during the 4th quarter. Nuveen Asset Management LLC now owns 81,574 shares of the company’s stock worth $875,000 after purchasing an additional 14,872 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Janux Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 204,002 shares of the company’s stock valued at $2,189,000 after purchasing an additional 11,317 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $52.65 on Monday. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of -39.29 and a beta of 4.18. The business has a 50 day simple moving average of $31.14 and a 200 day simple moving average of $16.81. Janux Therapeutics has a 52-week low of $5.65 and a 52-week high of $58.69.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The company had revenue of $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. On average, analysts predict that Janux Therapeutics will post -1.41 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.